The complaint centers on claims that ARS Pharmaceuticals violated the Securities Exchange Act by issuing false or misleading statements. Plaintiffs allege the firm recklessly disregarded risks surrounding the inclusion of its drug, neffy, in the CVS Caremark formulary. According to the filing, management failed to accurately disclose how timeline shifts would impact insurance coverage and the product's overall market rollout.

Investors who suffered losses during the specified class period may seek appointment as lead plaintiff, though such a role is not required to share in any potential recovery. Attorneys Brian Schall and David Schwartz are overseeing the case from the firm's Los Angeles office. Until the court certifies the class, shareholders remain unrepresented and are considered absent class members unless they take affirmative steps to join the action.